Beta-Adrenergic Blockade in Advanced Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Multicentric Study.

Autor:	Duarte Mendes A; Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT., Freitas AR; Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT., Vicente R; Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT., Ferreira R; Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT., Martins T; Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT., Ramos MJ; Medical Oncology Department, Centro Hospitalar Universitário de Santo António, Porto, PRT., Baptista C; Medical Oncology Department, Hospital Beatriz Ângelo, Loures, PRT., Silva BM; Medical Oncology Department, Hospital Beatriz Ângelo, Loures, PRT., Margarido I; Medical Oncology Department, Hospital da Luz Lisboa, Lisboa, PRT., Vitorino M; Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT., Silva M; Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT., Braga S; Medical Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, PRT.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jan 13; Vol. 16 (1), pp. e52194. Date of Electronic Publication: 2024 Jan 13 (Print Publication: 2024).
DOI:	10.7759/cureus.52194
Abstrakt:	Introduction The standard treatment of cancer has dramatically improved with immune checkpoint inhibitors (ICIs). Despite their proven advantage, many patients fail to exhibit a meaningful and lasting response. The beta-adrenergic signalling pathway may hold significant promise due to its role in promoting an immunosuppressive milieu within the tumour microenvironment. Inhibiting β-adrenergic signalling could enhance ICI activity; however, blocking this pathway for this purpose has yielded conflicting results. The primary objective of this study was to evaluate the effect of beta-blocker use on overall survival and progression-free survival during ICI therapy. Methods A multicentric, retrospective, observational study was conducted in four Portuguese institutions. Patients with advanced non-small cell lung cancer treated with ICIs between January 2018 and December 2019 were included. Those using beta blockers for non-oncological reasons were compared with non-users. Results Among the 171 patients included, 36 concomitantly received beta blockers and ICIs. No significant increase was found in progression-free survival among patients who took β-blockers (HR 0.74, 95% confidence interval (CI) 0.48-1.12, p = 0.151), and no statistically significant difference was found in overall survival. An apparent trend was observed towards better outcomes in the beta-blocker group, with a median overall survival of 9.93 months in the group not taking β-blockers versus 14.90 months in the β-blocker group (p = 0.291) and a median progression-free survival of 5.37 in the group not taking β-blockers versus 10.87 months in the β-blocker group (p = 0.151). Nine (25%) patients in the beta-blocker group and 16 (12%) in the non-beta-blocker group were progressive disease-free at the end of follow-up. This difference between the two groups is statistically significant (p = 0.047). Conclusion Our study found no statistically significant evidence that beta blockers enhance the effectiveness of immunotherapy. Using adrenergic blockade to modulate the immune system shows promise, warranting the need to develop prospective clinical studies. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Duarte Mendes et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu